Noninvasive blood tests to guide personalized cancer treatment

Why Blood?

Current molecular tests rely on invasive tumor biopsy procedures that put patients at risk and leave clinicians without timely information as cancer evolves. We overcome these limitations by exploiting the fact that many solid tumors release DNA into the bloodstream. Through the use of highly sensitive genetic analysis methods, we enable deep interrogation of this circulating tumor DNA for a range of diagnostic applications that are not possible with conventional biopsy-based testing methods:
  • Safely identify actionable mutations to guide therapy selection
  • Detect disease progression earlier
  • Monitor therapeutic efficacy over time
  • Characterize acquired drug resistance
  • Obtain a molecular estimate of tumor burden
  • Track tumor evolution


Our circulating tumor DNA analysis platform integrates a novel molecular targeting system with proprietary informatics methods to dramatically improve the detection capabilities of next-generation sequencing. This technology enables comprehensive analysis of all types of tumor-derived genomic alterations in an unbiased manner.
Fusions • Amplifications • INDELS • BASE SUBSTITUTIONS


  • Diagnostics
  • Our first clinical test, a pan-therapy companion diagnostic for molecularly targeted therapies, is currently being validated in collaboration with leading cancer researchers.

  • Research
  • We provide custom analysis and testing services to address a wide range of translational research and biomarker discovery applications.

  • Trials
  • We will offer assay development and validation services to support clinical trial testing through our CLIA laboratory starting in 2015.

About Us

Clearfork Bioscience was founded in 2012 by leading experts in next generation sequencing, genomic analysis and commercial product development. Our mission is to transform cancer outcomes by providing physicians and pharmaceutical companies with noninvasive diagnostic tools to guide the development and clinical implementation of personalized treatment strategies.
  • Chris Armour
  • Chief Executive Officer
  • Chris is an innovator with extensive experience in genomic technology development and product creation. At NuGEN Technologies, he created commercial applications for the next-generation sequencing market including new product families for RNA profiling and cancer gene sequencing. Prior to that, Chris spent 11 years at Rosetta Inpharmatics where he co-invented genomic tiling arrays and other breakthrough technologies that yielded discoveries ranging from new drug targets to cryptic activities of pharmaceutical compounds such as 5-FU. He began his career at the Fred Hutchinson Cancer Research Center and holds a BS from the University of Washington.
  • Chris Raymond, PhD
  • Chief Scientific Officer
  • Chris is an expert in genome sequencing, with a track record of inventing important new techniques. Previously at NuGEN Technologies, he led an R&D team that created cutting edge sample preparation methods for next-generation sequencing. At Merck Research Laboratories, Chris invented novel assay technologies to measure global copy number variation in cancer genomes, microRNA dynamics in colorectal cancer and somatic mutations in clinical tumor biopsies. His intellectual property portfolio forms the basis of several products commercialized by major life science companies. Chris holds B.S. and Ph.D. degrees in Chemistry from the University of California at Santa Cruz and the University of Oregon.
  • Lee Lim, PhD
  • Chief Technology Officer
  • Lee is an expert in deciphering the complex biology behind genome sequences. His work has led to fundamental discoveries in RNA biology and has been featured in high profile papers published in leading scientific journals. At the Rosetta Inpharmatics and Sirna divisions of Merck Research Laboratories, Lee pioneered the use of microRNAs as plasma biomarkers, elucidated a microRNA component of the p53 tumor suppressor pathway, and developed microRNA mimics for anti-cancer therapeutic applications. He holds a bachelor’s degree from Stanford University and a Ph.D. from Massachusetts Institute of Technology. Lee is a recipient of the AAAS Newcomb Cleveland Prize.